Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 7, 2015; 21(13): 3904-3911
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3904
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3904
Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C
Haruya Ishiguro, Hiroshi Abe, Nobuyoshi Seki, Tomonori Sugita, Yuta Aida, Munenori Itagaki, Satoshi Sutoh, Yoshio Aizawa, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine Katsushika Medical Center, Tokyo 125-8506, Japan
Noritomo Shimada, Department of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Chiba 270-0034, Japan
Tomomi Furihata, Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan
Akihito Tsubota, Core Research Facilities for Basic Science, Research Center for Medical Science, Jikei University School of Medicine, Tokyo 105-8461, Japan
Author contributions: Ishiguro H, Abe H, Sutoh S and Aizawa Y designed the research; Furihata T and Tsubota A examined the IFNL3 polymorphism; Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M and Shimada N analyzed the data; Ishiguro H, Abe H, Tsubota A and Aizawa Y wrote the paper.
Ethics approval: The study was reviewed and approved by the Jikei University School of Medicine Institutional Review Board.
Informed consent: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest: All authors declare no conflicts of interest.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Haruya Ishiguro, MD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine Katsushika Medical Center, 6-41-2 Aoto, Katsushika-ku, Tokyo 125-8506, Japan. haruya713@yahoo.co.jp
Telephone: +81-3-36032111 Fax: +81-3-38389944
Received: September 16, 2014
Peer-review started: September 19, 2014
First decision: November 5, 2014
Revised: November 29, 2014
Accepted: January 16, 2015
Article in press: January 16, 2015
Published online: April 7, 2015
Peer-review started: September 19, 2014
First decision: November 5, 2014
Revised: November 29, 2014
Accepted: January 16, 2015
Article in press: January 16, 2015
Published online: April 7, 2015
Core Tip
Core tip: Interferon-λ3 (IFNL3) single nucleotide polymorphisms (SNPs), such as rs8099917 and rs12979860, affect the virologic responses of chronically hepatitis C virus genotype 1-infected patients to response-guided pegylated interferon-α plus ribavirin therapy. However, the significance of these SNPs in therapy for hepatitis C virus genotype 2 (G2)-infected patients is unclear. We show that rs8099917 significantly influences sustained virologic response (SVR) achievement only in patients who do not attain rapid virologic response. Therefore, IFNL3 SNP genotyping is valuable for predicting SVR only in non-rapid virologic response patients, irrespective of the G2 subtype, even when therapy is extended up to 48 wk.